Details

Autor(en) / Beteiligte

• Levine, Richard J
• Maynard, Sharon E
• Qian, Cong
• Lim, Kee-Hak
• England, Lucinda J
• Yu, Kai F
• Schisterman, Enrique F
• Thadhani, Ravi
• Sachs, Benjamin P
• Epstein, Franklin H
• Sibai, Baha M
• Sukhatme, Vikas P
• Karumanchi, S. Ananth

Titel

Circulating Angiogenic Factors and the Risk of Preeclampsia

Ist Teil von

• The New England journal of medicine, 2004-02, Vol.350 (7), p.672-683

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In this nested case–control study, increased levels of soluble fms-like tyrosine kinase 1 (which binds placental growth factor) and reduced levels of placental growth factor — changes that have been implicated in endothelial dysfunction — predicted the subsequent development of preeclampsia. A possible pathogenic role for these factors in the development of preeclampsia. Preeclampsia affects about 5 percent of pregnancies, resulting in substantial maternal and neonatal morbidity and mortality. 1 , 2 Although the cause remains unclear, the syndrome may be initiated by placental factors that enter the maternal circulation and cause endothelial dysfunction resulting in hypertension and proteinuria. 3 – 6 We and others have recently shown that soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in the placenta 5 , 7 and serum 5 , 8 , 9 of women with preeclampsia. This protein acts by adhering to the receptor-binding domains of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), preventing their interaction with . . .